Ferric Sulfate

drug
On this page

Also known as Amersep-5320Ferric persulfateFerric sulfate anhydrousFerric sulfate hydrateFerric sulphate hydrateFerric trisulfate pentahydrateIron sesquisulfateIron sulfate (fe2(so4)3)Iron sulfate (fe2(so4)3) hydratePix 115Viscostat

Summary

Ferric Sulfate (CHEMBL5095046) is a phase-3 clinical-stage small molecule; indicated across 1 condition including pulpitis.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Indications: 1 condition
  • Clinical trials: 7

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL5095046
NameFerric Sulfate
TypeSmall molecule
Max phase3

Also known as: Amersep-5320, Ferric persulfate, Ferric sulfate, Ferric sulfate anhydrous, Ferric sulfate hydrate, Ferric sulphate hydrate, Ferric trisulfate pentahydrate, Iron sesquisulfate, Iron sulfate (fe2(so4)3), Iron sulfate (fe2(so4)3) hydrate, Pix 115, Viscostat

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

Clinical trials

Total trials: 7.

Phase distribution

PhaseTrials
Not specified4
PHASE41
PHASE21
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05358509PHASE4COMPLETEDReducing Anemia in Pregnancy in India: the RAPIDIRON Trial
NCT07541976PHASE2ACTIVE_NOT_RECRUITINGComparative Evaluation of Three Different Pulpotomy Agents in Primary Molars
NCT05557812EARLY_PHASE1COMPLETEDA Clinical Trial Comparing FS With ZOE and Non-eugenol Based Materials in Primary Teeth Pulpotomies
NCT02783911Not specifiedTERMINATEDComparison of Mineral Trioxide Aggregate (MTA) & Ferric Sulfate (FS) Pulpotomies
NCT05504863Not specifiedUNKNOWNRAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study
NCT05545527Not specifiedCOMPLETEDNeuroimaging Ancillary Study
NCT07120321Not specifiedCOMPLETEDPulpotomy Materials in Primary Molars

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.